Aptorum Group Limited - Class A Ordinary Shares (APM): Price and Financial Metrics
APM Price/Volume Stats
| Current price | $2.17 | 52-week high | $13.00 |
| Prev. close | $2.46 | 52-week low | $1.72 |
| Day low | $2.17 | Volume | 9,400 |
| Day high | $2.50 | Avg. volume | 168,600 |
| 50-day MA | $2.13 | Dividend yield | N/A |
| 200-day MA | $3.30 | Market Cap | 7.75M |
APM Stock Price Chart Interactive Chart >
APM Stock Summary
- With a market capitalization of $8,176,969, APTORUM GROUP LTD has a greater market value than only 4.75% of US stocks.
- With a one year PEG ratio of 0.33, APTORUM GROUP LTD is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.67% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, APTORUM GROUP LTD is reporting a growth rate of -251.73%; that's higher than merely 5.96% of US stocks.
- If you're looking for stocks that are quantitatively similar to APTORUM GROUP LTD, a group of peers worth examining would be LGVN, FBIO, INFN, RYTM, and CYCN.
- APM's SEC filings can be seen here. And to visit APTORUM GROUP LTD's official web site, go to www.aptorumgroup.com.
APM Valuation Summary
- APM's price/sales ratio is 6.3; this is 57.5% higher than that of the median Healthcare stock.
- Over the past 58 months, APM's EV/EBIT ratio has gone up 62.3.
Below are key valuation metrics over time for APM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| APM | 2023-09-18 | 6.3 | 0.5 | -0.8 | -1.0 |
| APM | 2023-09-15 | 7.3 | 0.6 | -1.0 | -1.1 |
| APM | 2023-09-14 | 7.6 | 0.6 | -1.0 | -1.2 |
| APM | 2023-09-13 | 7.6 | 0.6 | -1.0 | -1.2 |
| APM | 2023-09-12 | 7.4 | 0.6 | -1.0 | -1.1 |
| APM | 2023-09-11 | 6.2 | 0.5 | -0.8 | -1.0 |
APM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APM has a Quality Grade of C, ranking ahead of 44.63% of graded US stocks.
- APM's asset turnover comes in at 0.027 -- ranking 360th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows APM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.027 | -0.114 | 0.220 |
| 2019-12-31 | 0.016 | -0.485 | -0.814 |
APM Price Target
For more insight on analysts targets of APM, see our APM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Aptorum Group Limited - Class A Ordinary Shares (APM) Company Bio
Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
Latest APM News From Around the Web
Below are the latest news stories about APTORUM GROUP LTD that investors may wish to consider to help them evaluate APM as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning! |
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital MarketsNEW YORK, August 10, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockhold |
10 Oversold Global Stocks To BuyIn this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like July, August is full of surprises on the data front. After the U.S. economy grew quite […] |
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaNEW YORK & LONDON & PARIS, June 22, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA. The Phase 1b/2a study of SACT-1 submitted is for the combination with |
Aptorum Group Limited Announces Voluntary Delisting from Euronext ParisNEW YORK & LONDON & PARIS, June 09, 2023--Regulatory News: Aptorum Group Limited (the "Company") (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the "Aptorum Shares") (ISIN KYG6096M1226) from Euronext Paris. The Board of Euronext has approved this request. |
APM Price Returns
| 1-mo | -1.36% |
| 3-mo | -19.03% |
| 6-mo | -35.22% |
| 1-year | -81.45% |
| 3-year | -82.64% |
| 5-year | N/A |
| YTD | -60.55% |
| 2022 | -63.33% |
| 2021 | -39.27% |
| 2020 | -84.42% |
| 2019 | 4.41% |
| 2018 | N/A |
Loading social stream, please wait...